mProX™ Human CD93 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD93 is a protein expressed by brain endothelial cells (BECs) and has potential applications in neurological and neurovascular conditions. It may serve as a sensitive plasma biomarker for cerebral small vessel disease and dementia risk. A study identified 28 BEC-enriched proteins in plasma, including CD93, which were associated with white matter lesion volumes, cerebral microhemorrhages, and lacunar infarcts. Another study focused on adenocarcinoma of the esophagogastric junction (AEG) and identified CD93 as a hub gene related to tumorigenesis. In chronic Leishmania infection, CD93 was found to be expressed in parasitized cells, including monocytes, macrophages, megakaryocytes, basophils, and natural killer cells. CD93 was also implicated in platelet activation and surface expression of the protease activated receptor 4 (PAR4). It supported platelet aggregation and stabilization of PAR4 on the cell surface. Additionally, CD93 and its natural ligands, IGFBP7 and MMRN2, were considered potential targets for antiangiogenic therapy in solid tumors. CD93 was found to play a role in angiogenesis and could be targeted to normalize tumor vasculature.